ZA201807903B - Methods of treating circadian rhythm sleep disorders - Google Patents
Methods of treating circadian rhythm sleep disordersInfo
- Publication number
- ZA201807903B ZA201807903B ZA2018/07903A ZA201807903A ZA201807903B ZA 201807903 B ZA201807903 B ZA 201807903B ZA 2018/07903 A ZA2018/07903 A ZA 2018/07903A ZA 201807903 A ZA201807903 A ZA 201807903A ZA 201807903 B ZA201807903 B ZA 201807903B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- sleep disorders
- circadian rhythm
- rhythm sleep
- treating circadian
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335599P | 2016-05-12 | 2016-05-12 | |
| US201662335611P | 2016-05-12 | 2016-05-12 | |
| US201662413976P | 2016-10-27 | 2016-10-27 | |
| US201662414599P | 2016-10-28 | 2016-10-28 | |
| US201662414606P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/032228 WO2017197160A1 (en) | 2016-05-12 | 2017-05-11 | Methods of treating circadian rhythm sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807903B true ZA201807903B (en) | 2021-04-28 |
Family
ID=58745465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07903A ZA201807903B (en) | 2016-05-12 | 2018-11-22 | Methods of treating circadian rhythm sleep disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11096941B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3454859B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6888026B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102511855B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109640998A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2017264871B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3022068A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2904625T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL291791B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX379318B (cg-RX-API-DMAC7.html) |
| MY (1) | MY199382A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2763493C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201809527UA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI795359B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017197160A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201807903B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201809527UA (en) * | 2016-05-12 | 2018-11-29 | Eisai R&D Man Co Ltd | Methods of treating circadian rhythm sleep disorders |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| MX2021016090A (es) * | 2019-06-26 | 2022-02-03 | Eisai R&D Man Co Ltd | Lemborexant para el tratamiento de problemas del sueño. |
| JP2022538170A (ja) * | 2019-06-26 | 2022-08-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 睡眠問題の治療のためのレンボレキサント |
| CA3151634A1 (en) * | 2019-09-13 | 2021-03-18 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating insomnia |
| US20240010629A1 (en) * | 2019-12-11 | 2024-01-11 | Teva Czech Industries S.R.O | Solid state form of lemborexant |
| MX2022008260A (es) * | 2020-01-16 | 2022-08-04 | Eisai R&D Man Co Ltd | Sustancia farmacologica de lemborexant y composicion medicinal que la comprende. |
| CN111450076A (zh) * | 2020-05-25 | 2020-07-28 | 安徽省逸欣铭医药科技有限公司 | 一种Lemborexant软胶囊组合物及其制备方法 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| JP2024527024A (ja) * | 2021-07-26 | 2024-07-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患に伴う不規則睡眠・覚醒リズム障害及び概日リズム睡眠障害を治療する方法における使用のためのレンボレキサント |
| CN116421605B (zh) * | 2022-01-04 | 2024-08-02 | 中国科学院脑科学与智能技术卓越创新中心 | Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用 |
| KR20250070087A (ko) * | 2022-09-23 | 2025-05-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신경변성 질병과 관련된 신경변성의 감소 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06009377A (es) * | 2004-02-20 | 2007-03-07 | Lifescape Biosciences Inc | Composiciones y metodos para regulacion del sueno. |
| WO2008026149A1 (en) * | 2006-08-28 | 2008-03-06 | Actelion Pharmaceuticals Ltd | 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists |
| MX2013003218A (es) | 2010-09-22 | 2013-06-28 | Eisai R&D Man Co Ltd | Compuestos de ciclopropano. |
| CA2863413A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| CN107810006B (zh) * | 2014-10-23 | 2021-03-30 | 卫材R&D管理有限公司 | 用于治疗失眠的组合物 |
| SG11201809527UA (en) * | 2016-05-12 | 2018-11-29 | Eisai R&D Man Co Ltd | Methods of treating circadian rhythm sleep disorders |
-
2017
- 2017-05-11 SG SG11201809527UA patent/SG11201809527UA/en unknown
- 2017-05-11 ES ES17725084T patent/ES2904625T3/es active Active
- 2017-05-11 AU AU2017264871A patent/AU2017264871B2/en active Active
- 2017-05-11 RU RU2018143809A patent/RU2763493C2/ru active
- 2017-05-11 KR KR1020187035708A patent/KR102511855B1/ko active Active
- 2017-05-11 KR KR1020237009013A patent/KR20230043227A/ko not_active Ceased
- 2017-05-11 CA CA3022068A patent/CA3022068A1/en active Pending
- 2017-05-11 WO PCT/US2017/032228 patent/WO2017197160A1/en not_active Ceased
- 2017-05-11 JP JP2018558728A patent/JP6888026B2/ja active Active
- 2017-05-11 MX MX2018013663A patent/MX379318B/es unknown
- 2017-05-11 EP EP17725084.2A patent/EP3454859B1/en active Active
- 2017-05-11 IL IL291791A patent/IL291791B2/en unknown
- 2017-05-11 MY MYPI2018002456A patent/MY199382A/en unknown
- 2017-05-11 US US16/300,335 patent/US11096941B2/en active Active
- 2017-05-11 CN CN201780039758.8A patent/CN109640998A/zh active Pending
- 2017-05-11 EP EP21208238.2A patent/EP4056180A1/en active Pending
- 2017-05-12 TW TW106115904A patent/TWI795359B/zh active
-
2018
- 2018-11-06 IL IL262803A patent/IL262803B/en unknown
- 2018-11-22 ZA ZA2018/07903A patent/ZA201807903B/en unknown
-
2021
- 2021-05-19 JP JP2021084719A patent/JP7150096B2/ja active Active
- 2021-07-27 US US17/443,650 patent/US20210353625A1/en active Pending
-
2023
- 2023-05-31 AU AU2023203418A patent/AU2023203418A1/en not_active Abandoned
-
2025
- 2025-07-10 AU AU2025205336A patent/AU2025205336A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807903B (en) | Methods of treating circadian rhythm sleep disorders | |
| IL263783A (en) | Quinazoline and indole compounds for the treatment of medical disorders | |
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| PT3122878T (pt) | Terapia de arnm para o tratamento de doenças oculares | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| ZA201901055B (en) | Treatment and prevention of sleep disorders | |
| IL269082A (en) | Methods for treating lysosomal disorders | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| ZA201903873B (en) | Methods of treating cochlear synaptopathy | |
| IL267229A (en) | Methods of treating ocular disorders | |
| IL275654A (en) | Methods of treating CASTOR-related disorders | |
| ZA201902091B (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| ZA202002910B (en) | Treatment of skin disorders | |
| IL267044A (en) | Photodynamic therapeutic compounds and photodynamic treatment methods | |
| EP3151824A4 (en) | Methods of treating neurodevelopmental diseases and disorders | |
| IL265971B (en) | Therapeutic materials and methods for their production | |
| GB201520600D0 (en) | Treatment of central nervous tumours | |
| IL248385A0 (en) | Treatment of circadian rhythm disorder | |
| EP3558288A4 (en) | L-PAG DERIVATIVES FOR THE TREATMENT OF RESPIRATORY SLEEP DISORDERS (SDB) | |
| GB201604359D0 (en) | Treatment of tissue disorders |